Cargando…

Evaluating Glycemic Control Efficacy and Safety of the Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron in Type 2 Diabetes Patients: A Systemic Review and Meta-Analysis

INTRODUCTION: Diabetes Mellitus (DM) is a significant global health concern, with Type 2 DM (T2DM) being highly prevalent. Glucagon-Like Peptide 1 receptor agonists (GLP-1RA), such as Danuglipron, offer potential benefits in T2DM management. This meta-analysis examines the safety and efficacy of Dan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fatima, Hareer, Rangwala, Hussain Sohail, Mustafa, Muhammad Saqlain, Shafique, Muhammad Ashir, Abbas, Syed Raza, Rizwan, Azra, Fadlalla Ahmed, Tagwa Kalool, Arshad, Ainan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638946/ https://www.ncbi.nlm.nih.gov/pubmed/37954886 http://dx.doi.org/10.2147/DMSO.S439587

Ejemplares similares

Advances in Polatuzumab Vedotin-PIIQ Therapy: A Review of Treatment Efficacy in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma
por: Abdur Raqib, Moosa, et al.
Publicado: (2023)

Assessment Precision of CT Perfusion Imaging in the Detection of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
por: Mubarak, Fatima, et al.
Publicado: (2023)

Ultrasound renal denervation: the future of hypertension management?
por: Ali, Laiba, et al.
Publicado: (2023)

Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin
por: Shafique, Muhammad Ashir, et al.
Publicado: (2023)

Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial
por: Saxena, Aditi R., et al.
Publicado: (2023)

Analyzing safety and effectiveness of Mavacamten in comparison with placebo for managing hypertrophic cardiomyopathy: a systemic review and meta-analysis
por: Rangwala, Hussain Sohail, et al.
Publicado: (2023)

Rising HIV cases in Pakistan: Start of a pandemic?
por: Rangwala, Hussain Sohail, et al.
Publicado: (2022)

A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF‐06882961), an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, in Japanese adults with type 2 diabetes mellitus
por: Ono, Ryosuke, et al.
Publicado: (2022)

Viewing the Brain Through Retina: A New Avenue for Early Diagnosis of Alzheimer’s Disease
por: Zuhair, Varisha, et al.
Publicado: (2023)

Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists
por: Handelsman, Yehuda, et al.
Publicado: (2018)

Glycemic Control Impact on Body Weight Potential to Reduce Cardiovascular Risk: Glucagon-like peptide 1 agonists
por: Sesti, Giorgio
Publicado: (2011)

Glycemic monitoring with once-weekly Glucagon-like peptide 1 receptor agonist (GLP1RA) use
por: Kalra, Sanjay, et al.
Publicado: (2015)

Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes
por: Risovic, Ivona, et al.
Publicado: (2023)

Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis
por: Yeh, Tzu-Lin, et al.
Publicado: (2023)

The molecular pharmacology of glucagon agonists in diabetes and obesity
por: Novikoff, Aaron, et al.
Publicado: (2023)

Glucagon-Like Peptide-1 Receptor Agonist Semaglutide Improves Eating Behavior and Glycemic Control in Japanese Obese Type 2 Diabetic Patients
por: Masaki, Takayuki, et al.
Publicado: (2022)

Acute myocardial infarction from a lower-middle income country—A comprehensive report on performance measures and quality metrics using National Cardiovascular Data Registry
por: Baloch, Farhala, et al.
Publicado: (2023)

Boc5, a Non-Peptidic Glucagon-Like Peptide-1 Receptor Agonist, Invokes Sustained Glycemic Control and Weight Loss in Diabetic Mice
por: Su, Haoran, et al.
Publicado: (2008)

Vasopressin in Conjunction With Norepinephrine in Septic Shock: A Retrospective Cohort Study From a Low Middle-Income Country
por: Raza, Hussain Ahmed, et al.
Publicado: (2020)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Conformation Transition of Intracellular Part of Glucagon Receptor in Complex With Agonist Glucagon by Conventional and Accelerated Molecular Dynamics Simulations
por: Bai, Qifeng, et al.
Publicado: (2019)

Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
por: Li, Zhixia, et al.
Publicado: (2016)

Role of a Dual Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in Glycemic Control: From Pathophysiology to Treatment
por: Pelle, Maria Chiara, et al.
Publicado: (2021)

Glucagon-like peptide 1 improved glycemic control in type 1 diabetes
por: Behme, Margaret T, et al.
Publicado: (2003)

The Role of Glucagon in Glycemic Variability in Type 1 Diabetes: A Narrative Review
por: Guo, Keyu, et al.
Publicado: (2021)

Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short‐acting and other glucagon‐like peptide‐1 receptor agonists
por: Giorgino, Francesco, et al.
Publicado: (2016)

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists
por: Zhang, Yu-Juan, et al.
Publicado: (2013)

Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012)

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
por: Hinnen, Deborah
Publicado: (2017)

The potential of glucagon-like peptide-1 receptor agonists in heart failure
por: Kreiner, Frederik Flindt, et al.
Publicado: (2022)

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
por: Delgado, A., et al.
Publicado: (2021)

Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
por: Wojtara, Magda, et al.
Publicado: (2023)

Effects of glucagon like peptide-1 to mediate glycemic effects of weight loss surgery
por: Salehi, Marzieh, et al.
Publicado: (2014)

Glucagon-Like Peptide 1 Receptor Activation and Platelet Function: Beyond Glycemic Control
por: Jia, Guanghong, et al.
Publicado: (2016)

The Change in Glucagon Following Meal Ingestion Is Associated with Glycemic Control, but Not with Incretin, in People with Diabetes
por: Yoo, Soyeon, et al.
Publicado: (2021)

Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes
por: Eriksson, Olof, et al.
Publicado: (2020)

Is Pakistan prepared to tackle the coronavirus epidemic?
por: Saqlain, Muhammad, et al.
Publicado: (2020)

A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes
por: Baxter, Mike, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4p77a7f66sitalm2bu5vu8cq9u